Skip to main content
OpenTrials
Completed

NCT Number: NCT03659201

Efficacy and Safety of Neosil on Chronic Effluvium

The purpose of this study is to evaluate the efficacy of Neosil in the treatment of chronic effluvium

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

Caep Centro Avancado de Estudos E Pesquisas Ltda

Campinas, São Paulo, 13083190, Brazil

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants who present hair loss for more than 6 months;
  • Do not use other possible cosmetic or dermatological treatments, during the trial;
  • Not change the diet during the trial and not be any restrictive diet during this period.

Exclusion criteria

  • Pregnancy or risk of pregnancy and lactating patients;
  • Use of any products to promote hair growth within the 6 months prior to the Baseline Visit;
  • History of hair transplants;
  • Current skin disease;
  • History hypersensitivity to the active ingredients used in the study;
  • Participation in clinical trial in the year prior to this study;
  • Known history of non controled systemic disease (diabetes, hypertension, anemia, iron deficiency, and others);
  • Gastric diseases;
  • Smoker;
  • History of systemic disease (HIV, non specify autoimmune disease, hepatitis, and others).

Treatment and study plan

Neosil complete

Drug

Oral, during 24 weeks.

Pantogar

Drug

Oral, placebo for 12 weeks and pantogar for 12 weeks.

Neosil

Drug

Oral, during only 12 weeks.

Primary outcomes

  1. Hair density

    Time frame: 24 weeks

Secondary outcomes

  1. Incidence and severity of adverse events recorded during the study

    Time frame: 24 weeks

Sponsors and collaborators

Lead sponsor

EMS

Industry

Collaborators

  • Luxbiotech

Registry information

Official study title

Randomized Clinical Trial, Placebo Controlled and Active Comparator, to Evaluate Efficacy and Safety of Neosil in Chronic Effluvium

Important dates

Study start
2018
Primary completion
2019
Study completion
2020
First posted
Sep 6, 2018
Registry last updated
Apr 7, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.